Company news

IDEAYA Biosciences, Inc. news in 2023

IDEAYA Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event

December 4, 2023

IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer

December 3, 2023

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023

December 2, 2023

IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference

October 31, 2023

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

October 22, 2023

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma

October 16, 2023

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma

October 15, 2023

IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day

October 8, 2023

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer

September 26, 2023

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations

September 25, 2023

IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors

September 10, 2023

IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events

September 4, 2023

IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)

August 20, 2023

IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma

August 15, 2023

IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023

IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors

August 1, 2023

IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event

July 31, 2023

IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy

June 21, 2023

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

June 11, 2023

IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events

May 29, 2023

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

May 21, 2023

IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma

May 15, 2023

IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event

April 30, 2023

IDEAYA Announces Proposed Public Offering of Common Stock

April 23, 2023

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma

April 22, 2023

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors

April 18, 2023

IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event

April 2, 2023

IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase

March 13, 2023

IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update

March 6, 2023

IDEAYA Biosciences to Participate in Investor Conferences in March 2023

February 28, 2023

IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit

February 15, 2023

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference

January 31, 2023

IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

January 22, 2023

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161

January 8, 2023

IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

January 2, 2023

Decks in 2023